ImmunoCellular Therapeutics Announces Research Agreement with George Mason University...

ImmunoCellular Therapeutics Announces Research Agreement with George Mason University for Detection of Certain Cancers

LOS ANGELES--(Business Wire)--
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a
biotechnology company, today announced that the company has signed a
research agreement with George Mason University for the development of
a blood test to detect small cell lung cancer and pancreatic cancer
using IMUC's monoclonal antibody technology. The blood-based test
would be designed to look for certain markers for the cancers
potentially allowing for early detection of these cancers as well as
assisting the selection of patients most likely to respond to the
company's monoclonal antibody therapy, ICT-109.

"We are excited to be working with such a renowned scientist, Dr.
Emanuel Petricoin, and his team at George Mason University, as his
work in the development of personalized medicines and the application
of proteomics in cancer detection is highly regarded, including his
past work on cancer biomarker discovery for ovarian and prostate
cancer early detection," stated Dr. Manish Singh, president and chief
executive officer of ImmunoCellular Therapeutics. "We were pleased to
present exciting pre-clinical data from our antibody program at last
week's American Society for Clinical Oncology meeting demonstrating
the ability to detect dramatic disparities between cancer types,
potentially allowing for the development of discerning therapeutics
for specific cancers, thereby enabling greater safety and efficacy."

"We look forward to working with ImmunoCellular Therapeutics and
working toward the validation and verification of their candidate
biomarkers, as we are intrigued by the preclinical data collected to
date," stated Dr. Petricoin, professor of Life Sciences and
co-director, Center for Applied Proteomics and Molecular Medicine,
George Mason University. "Small cell lung cancer and pancreatic cancer
are two of many cancers where patients could benefit from early
detection, so we will seek to develop a simple blood test using IMUC's
antibody technology that might enable these cancers to be discovered
early, which could ultimately dramatically improve a patient's
prognosis. This work will greatly assist our University CAP-CLIA
compliant proteomics laboratory module the necessary proficiency
testing towards full accreditation of the laboratory."

IMUC, through its recent acquisition of monoclonal
antibody-related technology from Molecular Discoveries LLC, has
several novel monoclonal antibodies. ICT-109, the company's lead
antibody, is a monoclonal antibody targeting small cell lung cancer
and pancreatic cancer. This candidate is currently in pre-clinical
development, and the company plans to couple it with a diagnostic kit
to prescreen patients for the specific antigens that bind to ICT-109.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based development stage company that is
developing immune-based therapies for the treatment of brain and other
cancers. IMUC's lead product candidate--a dendritic cell-based vaccine
for treating brain tumors--is currently being evaluated in a Phase I
clinical trial. Additionally, the company is developing a therapeutic
vaccine targeting cancer stem cells for multiple cancer indications
and is also evaluating its newly acquired monoclonal antibody-related
technology for diagnosing and treating multiple types of cancer. To
learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
without limitation the need to confirm pre-clinical data
characterizing distinct antigens between cancers; the risk that
therapeutics based on markers detected by IMUC's technology will not
prove to be safer or more efficacious than alternative therapies; the
continuation of research agreements, including the antibody agreement
with George Mason University; the need for substantial additional
capital to fund development of product candidates beyond their initial
clinical or pre-clinical stages; and the risks associated with
pre-clinical and clinical development of product candidates.
Additional risks and uncertainties are described in IMUC's most
recently filed SEC documents, such as its most recent annual report on
Form 10-KSB, all quarterly reports on Form 10-Q and any current
reports on Form 8-K, IMUC undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

ImmunoCellular Therapeutics, Ltd.
Jennifer Cook Williams
Investor Relations
360-668-3701

Copyright Business Wire 2008